CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article
Click on image to view larger version.



Fig. 8. Role of growth factors on the differentiating activity of pharmacological differentiating agents. U937 cells were incubated for 120 h in the absence (Control) or presence of hydroxyurea (100 µg/ml) or phenylbutyrate (1.5 mM) along with neutralizing antihuman GM-CSF (0.1 mg/ml) and antihuman IL-3 (0.15 mg/ml) or nonbinding isotypic control antibodies and assessed for CD11b expression (A) and clonogenic growth (B). All results represent the means of three separate experiments; bars, SE. Ps compare agents treated with blocking antibodies or control antibodies by the paired Student’s t test.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation